Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.

Original languageEnglish (US)
Pages (from-to)1857-1862
Number of pages6
JournalFuture Oncology
Volume6
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Antineoplastic Agents
Neoplasms
Mutation
Therapeutics

Keywords

  • 37AA
  • apoptosis
  • CP-31398
  • mdm2
  • Nutlin
  • p63
  • p73
  • PRIMA-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. / Martinez, Jesse D.

In: Future Oncology, Vol. 6, No. 12, 12.2010, p. 1857-1862.

Research output: Contribution to journalArticle

@article{c318b28c79fe4f9f97bc8bd03d6b1991,
title = "Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy",
abstract = "Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.",
keywords = "37AA, apoptosis, CP-31398, mdm2, Nutlin, p63, p73, PRIMA-1",
author = "Martinez, {Jesse D}",
year = "2010",
month = "12",
doi = "10.2217/fon.10.132",
language = "English (US)",
volume = "6",
pages = "1857--1862",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy

AU - Martinez, Jesse D

PY - 2010/12

Y1 - 2010/12

N2 - Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.

AB - Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.

KW - 37AA

KW - apoptosis

KW - CP-31398

KW - mdm2

KW - Nutlin

KW - p63

KW - p73

KW - PRIMA-1

UR - http://www.scopus.com/inward/record.url?scp=78650492863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650492863&partnerID=8YFLogxK

U2 - 10.2217/fon.10.132

DO - 10.2217/fon.10.132

M3 - Article

C2 - 21142860

AN - SCOPUS:78650492863

VL - 6

SP - 1857

EP - 1862

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12

ER -